CLRB

Cellectar Biosciences, Inc.
CAPPED RATING

Cellectar Biosciences Inc is a biopharmaceutical company. It is engaged in developing compounds for treatment and imaging of cancer. Its portfolio consists of PET imaging agents, optical imaging agents, and therapeutic agents.

Cellectar Biosciences, Inc. (CLRB) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.6
EV / EBITDA 0.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -53.1%
Price Return 12M -64.0%
Catalyst Signal 0.00
Market Cap $11.5M
TTM Revenue N/A
Price / Sales N/A
ROE -119.6%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.7) C- (2.1) C (2.3) D- (1.0) C+ (2.6) C (2.3)
2026-11-04 B+ (3.7) C (2.2) C (2.3) D- (1.1) C+ (2.7) C (2.4)
2026-10-28 B+ (3.6) C- (2.1) C (2.3) D (1.2) C+ (2.7) C (2.4)
2026-10-21 B+ (3.6) C- (2.1) C (2.3) D (1.4) C+ (2.6) C (2.4)
2026-10-14 B+ (3.7) C- (2.1) C (2.3) D (1.4) C+ (2.6) C (2.4)
Page 1 of 4